Journal
EXPERT OPINION ON BIOLOGICAL THERAPY
Volume 18, Issue 8, Pages 905-910Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/14712598.2018.1499722
Keywords
Hepatocellular carcinoma; receptor tyrosine kinase inhibitor; sorafenib; immunotherapy; anti-CTLA-4; anti-PD1; anti-PD-L1; oncolytic virus; bispecific antibody; chimeric antigen receptor
Ask authors/readers for more resources
Introduction: Immunotherapy is on the way to become the new standard of care for advanced hepatocellular carcinoma (HCC) worldwide. With higher rates of objective responses, and overall less side effects compared to tyrosine-kinase inhibitors (TKIs) immunotherapeutics will probably replace sorafenib from standard first-line treatment. Areas covered: This review covers recent clinical data on systemic agents and ongoing trials in patients with advanced HCC focusing on immunotherapy. Expert opinion: In unselected patients with advanced HCC immunotherapeutics, namely the programmed cell death-1 (PD-1) antibodies, nivolumab and pembrolizumab have shown promising efficacy in therapy-naive, as well as pre-treated patients with advanced HCC. However, only 10-20 percent of treated patients show an objective and durable response to the indicated therapeutics. Therefore, combination therapies including different immunotherapeutics, e.g. PD-1/programmed cell death 1 ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibodies, or combinations of immunotherapeutics and small molecules, or bifunctional antibodies will be needed to improve response rates.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available